# SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

> **NCT04282070** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 91 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** SHR-1701
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Albumin Paclitaxel

## Key facts

- **NCT ID:** NCT04282070
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-27
- **Primary completion:** 2022-04-16
- **Final completion:** 2022-12-15
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04282070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04282070, "SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04282070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*